{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:14:16Z","timestamp":1788952456179,"version":"build-2803163510"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>ANCA are a key biomarker for ANCA-associated vasculitis (AAV), particularly microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Although indirect immunofluorescence (IIF) has traditionally been the reference technique, its diagnostic value in contemporary real-world practice remains uncertain. The aim of this study was to evaluate the diagnostic performance of IIF ANCA testing in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study of all patients with an ANCA request at a tertiary hospital over a 4-year period. All IIF-positive sera were subsequently tested for anti-PR3 and anti-MPO antibodies by chemiluminescent immunoassay (CLIA). Clinical data, test indication and final diagnoses were retrieved from electronic medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 5157 patients and IIF was positive in 653 (12.7%): perinuclear ANCA (P-ANCA) in 17.9%, cytoplasmic ANCA (C-ANCA) in 13.3% and atypical ANCA (A-ANCA) in 68.8%. CLIA was negative in 97.3% of A-ANCA. AAV was diagnosed in 47 patients, and 42 (89.4%) had positive IIF. For GPA and MPA, IIF showed a sensitivity of 93% and specificity of 88%, with a very high negative predictive value (NPV) (99.9%) but low positive predictive value (PPV) (6.1%). Specificity improved to 96.8% when restricted to typical patterns (C-ANCA or P-ANCA) and to 99.6% when combined with positive CLIA results &amp;gt;20\u2009IU\/ml. Almost all AAV cases were diagnosed in patients with high pre-test probability (such as renal disease, lung infiltrates or peripheral neuropathies) and interstitial lung disease was the most frequent non-AAV diagnosis in IIF-positive patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ANCA IIF retains good diagnostic efficiency and a very high NPV for GPA and MPA, but has low PPV, particularly when tested for nonspecific symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keag072","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:32:37Z","timestamp":1770121957000},"source":"Crossref","is-referenced-by-count":3,"title":["ANCA testing in real-world clinical practice: diagnostic performance and predictive value in a Spanish cohort"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6451-8971","authenticated-orcid":false,"given":"Jose","family":"Loureiro-Amigo","sequence":"first","affiliation":[{"name":"Systemic Autoimmune Diseases Unit, Internal Medicine Department, Hospital Universitari Vall d\u2019Hebron , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6612-221X","authenticated-orcid":false,"given":"Jaume","family":"Mestre-Torres","sequence":"additional","affiliation":[{"name":"Systemic Autoimmune Diseases Unit, Internal Medicine Department, Hospital Universitari Vall d\u2019Hebron , Barcelona,","place":["Spain"]},{"name":"Medicine Department, Universitat Aut\u00f2noma de Barcelona , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mar\u00edn-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Clinical Analysis and Immunology Department, Hospital Universitario Virgen de las Nieves , Granada,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vi\u00f1as Gim\u00e9nez","sequence":"additional","affiliation":[{"name":"Immunology Department, Hospital Universitari Vall d\u2019Hebron , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Sanz Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Immunology Department, Hospital Universitari Vall d\u2019Hebron , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Agraz Pamplona","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitari Vall d\u2019Hebron , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Solans-Laqu\u00e9","sequence":"additional","affiliation":[{"name":"Systemic Autoimmune Diseases Unit, Internal Medicine Department, Hospital Universitari Vall d\u2019Hebron , Barcelona,","place":["Spain"]},{"name":"Medicine Department, Universitat Aut\u00f2noma de Barcelona , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"2026022008515123700_keag072-B1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Prim"},{"key":"2026022008515123700_keag072-B2","first-page":"S112","article-title":"Review Antineutrophil cytoplasmic antibodies (ANCA) testing\u202f: detection methods and clinical application","volume":"32","author":"Sinico","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2026022008515123700_keag072-B3","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0140-6736(06)69114-9","article-title":"Antineutrophil cytoplasmic antibodies","volume":"368","author":"Bosch","year":"2006","journal-title":"Lancet"},{"key":"2026022008515123700_keag072-B4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrrheum.2017.140","article-title":"Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis","volume":"13","author":"Bossuyt","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2026022008515123700_keag072-B5","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1681\/ASN.0000000749","article-title":"Antineutrophil cytoplasmic autoantibodies: role in diagnosis, disease monitoring, and prognosis","volume":"36","author":"Wyatt","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"2026022008515123700_keag072-B6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1136\/jcp.2009.064485","article-title":"Appropriateness of antineutrophil cytoplasmic antibody testing in a tertiary hospital","volume":"62","author":"Robinson","year":"2009","journal-title":"J Clin Pathol"},{"key":"2026022008515123700_keag072-B7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/ajcp\/111.4.507","article-title":"International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA)","volume":"111","author":"Savige","year":"1999","journal-title":"Am J Clin Pathol"},{"key":"2026022008515123700_keag072-B8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrrheum.2014.78","article-title":"Current and emerging techniques for ANCA detection in vasculitis","volume":"10","author":"Csernok","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"2026022008515123700_keag072-B9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2249.2007.03453.x","article-title":"Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA)","volume":"150","author":"Talor","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"2026022008515123700_keag072-B10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12016-007-8071-9","article-title":"Antineutrophil cytoplasmic autoantibodies: how should the biologist manage them?","volume":"35","author":"Beauvillain","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026022008515123700_keag072-B11","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.3390\/jcm13175116","article-title":"Cocaine- and levamisole-induced vasculitis: defining the spectrum of autoimmune manifestations","volume":"13","author":"Iorio","year":"2024","journal-title":"J Clin Med"},{"key":"2026022008515123700_keag072-B12","doi-asserted-by":"crossref","first-page":"185416","DOI":"10.1155\/2014\/185416","article-title":"Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies","volume":"2014","author":"Schulte-Pelkum","year":"2014","journal-title":"J Immunol Res"},{"key":"2026022008515123700_keag072-B13","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1515\/cclm-2017-0306","article-title":"An international survey on anti-neutrophil cytoplasmic antibodies (ANCA) testing in daily clinical practice","volume":"56","author":"Damoiseaux","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"2026022008515123700_keag072-B14","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archinte.162.13.1509","article-title":"Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis: can test-ordering guidelines improve diagnostic accuracy?","volume":"162","author":"Mandl","year":"2002","journal-title":"Arch Intern Med"},{"key":"2026022008515123700_keag072-B15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/1529-0131(200012)13:6<424::AID-ART14>3.0.CO;2-Q","article-title":"Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions","volume":"13","author":"Stone","year":"2000","journal-title":"Arthritis Care Res"},{"key":"2026022008515123700_keag072-B16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/art.10997","article-title":"Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multiorgan dysfunction","volume":"49","author":"Vassilopoulos","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2026022008515123700_keag072-B17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/rheumatology\/40.2.178","article-title":"Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA","volume":"40","author":"Sch\u00f6nermarck","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"2026022008515123700_keag072-B18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2796.1998.00357.x","article-title":"Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies","volume":"244","author":"Franssen","year":"1998","journal-title":"J Intern Med"},{"key":"2026022008515123700_keag072-B19","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/annrheumdis-2016-209507","article-title":"Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays","volume":"76","author":"Damoiseaux","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026022008515123700_keag072-B20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/clim.2001.5200","article-title":"Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions","volume":"103","author":"Russell","year":"2002","journal-title":"Clin Immunol"},{"key":"2026022008515123700_keag072-B21","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/1756-185X.12926","article-title":"Antineutrophil cytoplasmic antibody (ANCA) testing: audit from a clinical immunology laboratory","volume":"20","author":"Phatak","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2026022008515123700_keag072-B22","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/qjmed\/94.11.615","article-title":"The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting","volume":"94","author":"McLaren","year":"2001","journal-title":"QJM"},{"key":"2026022008515123700_keag072-B23","first-page":"626495","article-title":"Antineutrophil cytoplasmic antibodies testing in a large cohort of unselected greek patients","volume":"2011","author":"Tsiveriotis","year":"2011","journal-title":"Autoimmune Dis"},{"key":"2026022008515123700_keag072-B24","first-page":"7","article-title":"[Antineutrophil cytoplasmic antibodies (ANCA): clinico-pathologic correlations iin a series of 82 cases]","volume":"19","author":"Calvo Romero","year":"2002","journal-title":"An Med Interna"},{"key":"2026022008515123700_keag072-B25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026022008515123700_keag072-B26","first-page":"e6083","article-title":"Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity","volume":"96","author":"Solans-Laqu\u00e9","year":"2017","journal-title":"Med (United States)"},{"key":"2026022008515123700_keag072-B27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jclinepi.2008.04.007","article-title":"Diagnostic test accuracy may vary with prevalence: implications for evidence-based diagnosis","volume":"62","author":"Leeflang","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"2026022008515123700_keag072-B28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1445-5994.2007.01436.x","article-title":"Cautionary tales in the clinical interpretation of studies of diagnostic tests","volume":"38","author":"Scott","year":"2008","journal-title":"Intern Med J"},{"key":"2026022008515123700_keag072-B29","doi-asserted-by":"crossref","first-page":"210123","DOI":"10.1183\/16000617.0123-2021","article-title":"Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review","volume":"30","author":"Kadura","year":"2021","journal-title":"Eur Res Rev"},{"key":"2026022008515123700_keag072-B30","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/MCP.0000000000000979","article-title":"Interstitial lung disease in patients with anti-neutrophil cytoplasm antibody-associated vasculitis: an update on pathogenesis and treatment","volume":"29","author":"Turgeon","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"2026022008515123700_keag072-B31","doi-asserted-by":"publisher","first-page":"100235","DOI":"10.1016\/j.jtauto.2024.100235","article-title":"Presentation and progression of MPO-ANCA interstitial lung disease","volume":"8","author":"Salvati","year":"2024","journal-title":"J Transl Autoimmun"},{"key":"2026022008515123700_keag072-B32","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.chest.2019.05.014","article-title":"prevalence and clinical significance of antineutrophil cytoplasmic antibodies in North American patients with idiopathic pulmonary fibrosis","volume":"156","author":"Liu","year":"2019","journal-title":"Chest"},{"key":"2026022008515123700_keag072-B33","first-page":"101111","article-title":"Interstitial lung diseases associated with ANCA positivity: a different disease spectrum from interstitial pneumonia with autoimmune features","volume":"86","author":"Zhu","year":"2024","journal-title":"Respir Med Res"},{"key":"2026022008515123700_keag072-B34","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/MCP.0000000000001187","article-title":"ANCA associated pulmonary fibrosis: vasculitis or not vasculitis","volume":"31","author":"Codes-M\u00e9ndez","year":"2025","journal-title":"Curr Opin Pulm Med"},{"key":"2026022008515123700_keag072-B35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.nefroe.2025.01.001","article-title":"Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis","volume":"45","author":"Morales","year":"2025","journal-title":"Nefrologia"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keag072\/66799552\/keag072.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keag072\/66799552\/keag072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keag072\/66799552\/keag072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T13:52:02Z","timestamp":1771595522000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keag072\/8466424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keag072","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,2]]},"article-number":"keag072"}}